EMA CHMP gives positive opinion on belantamab mafodotin combinations for relapsed/refractory myeloma patientsAccess, Myeloma28 May 2025
AL amyloidosis phase III clinical trial of birtamimab fails to meet primary endpointAL amyloidosis26 May 2025
European Commission approves linvoseltamab for the treatment of relapsed and refractory myelomaAccess, Myeloma29 April 2025
Register now to join the webinar ‘How do different countries make decisions on reimbursing new medicines?’Access, MPE6 March 2025
EMA CHMP gives positive opinion on linvoseltamab for relapsed/refractory myeloma patientsAccess, Myeloma, News3 March 2025
